Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen and Genoway to Co-Market RNAi Services

NEW YORK, Dec. 15 (GenomeWeb News) - Invitrogen and Genoway will co-market RNAi-related services, the companies said today.

 

Under the agreement, Invitrogen will combine its expertise in RNAi research technologies with Genoway's portfolio of transgenesis technologies and RNAi in vivo experience to create a new services platform. The platform will allow RNAi vector design through the creation of RNAi transgenic rodent models.

 

Both companies will share revenues, Genoway said.

 

Additional details were not disclosed.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.